Xenex LightStrike UV Robots Deactivate SARS-CoV-2 on Surfaces in 2 Minutes in New Peer-Reviewed Study

8-Oct-2020 4:15 PM EDT, by Xenex Disinfection Services

Newswise — The LightStrike pulsed xenon disinfection robot is the first ultraviolet (UV) room disinfection technology proven to deactivate SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus 2). The LightStrike robot achieved a greater than 99.99% level of disinfection against SARS-CoV-2, which is the virus that causes COVID-19, in two minutes. Testing was performed in a biosafety level 4 lab at Texas Biomedical Research Institute, one of the world’s leading independent research institutes working exclusively on infectious diseases.

The new peer-reviewed and published study, titled “Deactivation of SARS-CoV-2 with pulsed-xenon ultraviolet light: Implications for environmental COVID-19 control” is published in Infection Control and Hospital Epidemiology. The authors include highly regarded physicians and infectious disease experts from the Central Texas Veterans Healthcare System, HonorHealth, Mayo Clinic, Texas Biomedical Research Institute, The University of Texas MD Anderson Cancer Center, University of Michigan, University of California-San Francisco, West Virginia University Medicine, and Xenex.

“Deactivating SARS-CoV-2 on surfaces is a critical and necessary step to protect people as businesses and schools begin to reopen and people return to work. Individuals with COVID-19 and asymptomatic carriers of SARS-CoV-2 contaminate their environment, and SARS-CoV-2 has been shown to be viable on surfaces for up to three days,” said Dr. Mark Stibich, Chief Scientific Officer of Xenex. “We convened a panel of some of the world’s leading infectious disease experts to validate the efficacy of pulsed xenon UV disinfection against SARS-CoV-2, and to confirm the LightStrike robot’s role as an important tool in the battle against the pandemic.”

LightStrike Germ-Zapping Robots™ use a xenon lamp to generate bursts of high intensity, broad spectrum (200-315nm) UV light. Different pathogens are susceptible to UV light at different wavelengths. With broad spectrum UV light, Xenex LightStrike robots quickly deactivate viruses, bacteria and spores at the specific wavelengths of light where the pathogens are most vulnerable without damaging materials or surfaces. More than 40 peer-reviewed studies have been published validating the efficacy of the LightStrike technology, which is now being used not only in healthcare facilities but in hotels, schools, professional sports facilities, office buildings and corporate headquarters, airports, police stations and jails, government buildings, and food processing facilities.

Prior to peer-review, Xenex’s SARS-CoV-2 efficacy results were shared in a study published on medRxiv on May 11, 2020.

About Xenex

Xenex is a world leader in UV technology-based disinfection strategies and solutions, working closely with hospitals’ infection control and EVS personnel to reduce the presence of dangerous pathogens in their facilities to provide a safer environment for patients and staff. Xenex's mission is to save lives and reduce suffering by destroying the deadly microorganisms that can cause infections. Xenex is backed by well-known investors that include EW Healthcare Partners, Piper Jaffray, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures and RK Ventures. For more information, visit xenex.com.

 

###

 

 

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 5634
Newswise: shutterstock_1724336896.jpg
Released: 13-May-2021 12:55 PM EDT
Kreuter receives $1.9 million in grants to increase vaccinations in St. Louis
Washington University in St. Louis

Matthew Kreuter, the Kahn Family Professor of Public Health at the Brown School, has received $1.9 million in grants to help increase COVID-19 vaccinations among Blacks in St. Louis City and County.

Released: 13-May-2021 11:35 AM EDT
COVID-19 mRNA Vaccines are Immunogenic in Pregnant and Lactating Women, Including Against Viral Variants
Beth Israel Deaconess Medical Center

In a new study from Beth Israel Deaconess Medical Center researchers evaluated the immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women who received either the Pfizer or Moderna COVID-19 vaccines. They found that both vaccines triggered immune responses in pregnant and lactating women.

Released: 13-May-2021 10:30 AM EDT
Pandemic stigma: Foreigners, doctors wrongly targeted for COVID-19 spread in India
Monash University

The Indian public blamed foreigners, minority groups and doctors for the rapid spread of COVID-19 across the country during the first wave, due to misinformation, rumour and long-held discriminatory beliefs, according to an international study led by Monash University.

Released: 13-May-2021 9:00 AM EDT
28 Community Programs Receive Grants Through Penn Medicine CAREs Program
Perelman School of Medicine at the University of Pennsylvania

Penn Medicine CAREs awarded grants to 28 projects, many of which aim to fill vast needs in the community created by the COVID-19 pandemic, while others seek to improve diversity, equity, and inclusion.

Released: 13-May-2021 9:00 AM EDT
How to Win Over Vaccine Skeptics: Live Expert Panel for May 20, 3pm ET
Newswise

How to Win Over Vaccine Skeptics: Live Expert Panel for May 20, 3pm ET

Released: 13-May-2021 8:00 AM EDT
Dental procedures during pandemic are no riskier than a drink of water
Ohio State University

A new study’s findings dispel the misconception that patients and providers are at high risk of catching COVID-19 at the dentist’s office.

Newswise:Video Embedded lung-damage-not-the-culprit-for-post-covid-exercise-limitations
VIDEO
Released: 13-May-2021 7:00 AM EDT
Lung Damage Not the Culprit for Post-COVID Exercise Limitations
American Physiological Society (APS)

A new study suggests the lungs may not be the main factor that reduce exercise ability in people recovering from severe COVID-19. Anemia and muscle dysfunction also play a role. The study is published ahead of print in the Journal of Applied Physiology. It was chosen as an APSselect article for May.

Newswise:Video Embedded australia-accelerates-new-covid-19-vaccine-to-fight-mutant-strains
VIDEO
Released: 13-May-2021 2:05 AM EDT
Australia accelerates new COVID-19 vaccine to fight mutant strains
University of South Australia

A leading South Australian immunologist has been awarded $3 million from the Federal Government to accelerate work on a locally developed Covid-19 vaccine, in what's anticipated to be the second line of defence against the virus.

Released: 12-May-2021 5:10 PM EDT
Understanding SARS-COV-2 proteins is key to improve therapeutic options for COVID-19
Bentham Science Publishers

COVID-19 has had a significant impact since the pandemic was declared by WHO in 2020, with over 3 million deaths and counting, Researchers and medical teams have been hard at work at developing strategies to control the spread of the infection, caused by SARS-COV-2 virus and treat affected patients.


Showing results

110 of 5634

close
2.43224